Navigating Your Care
FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma
Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular l…
Meet The Researcher: Dr. Rayne Rouce
To commemorate Black History Month, LLS is highlighting exceptional clinicians and healthcare professionals throughout the month of February. Dr. Rayn…
Practicing Self-Advocacy During My PTCL Journey
The LLS Blog invites Aaron, who was diagnosed with peripheral T-cell lymphoma (PTCL), to share his reflections on becoming a self-advocate throughout …
Honoring My Daughter’s Legacy By Continuing Her Fight
Today is International Childhood Cancer Day, a day that had little significance for me less than four short years ago. In October 2017, I heard the wo…
Dare to Dream
Ushering In a New Era of Pediatric Blood Cancer Treatment and Care
We caught up with Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), to share the progress we’re making to bring cures …
Navigating Your Care
A New CAR-T Approval Brings Hope for Mantle Cell Lymphoma Patients
Meet the Researcher: Omar Abdel-Wahab, MD
Dr. Abdel-Wahab of Memorial Sloan Kettering Cancer Center focuses on an area of research called epigenetics – chemical modifications that regulate (sw…
